

# Middle East HEALTH

Serving the region for over 50 years

November - December 2025

## SUPPLEMENT



## At the Cutting Edge

Leading US hospitals demonstrate  
excellence in complex care  
and international patient services

*Supplement to Middle East Health*









# 10 Years

in a Row on the 'Best Hospitals'  
Honor Roll in the U.S.

Cedars-Sinai has been named to the Honor Roll for the 10th consecutive year and tied for No. 1 in California and Los Angeles in U.S. News & World Report's "Best Hospitals 2025-26" rankings.

Every year, thousands of patients from over 100 countries choose Cedars-Sinai for our renowned healthcare. From complex surgeries to rare diagnoses and second opinions, the Cedars-Sinai team ensures a seamless experience - before, during, and after care.

### Six Cedars-Sinai specialties were ranked in the top 10 in the U.S.:

-  Orthopedics
-  Pulmonology & Lung Surgery
-  Obstetrics & Gynecology
-  Gastroenterology & GI Surgery
-  Diabetes & Endocrinology
-  Cardiology, Heart & Vascular Surgery

Located in Los Angeles, California, Cedars-Sinai combines world-class care with a vibrant setting, cultural sensitivity, and concierge-level comfort.



Learn more

[cedars-sinai.org/international](https://cedars-sinai.org/international)  
[cedars-sinai.org/globalcollaborations](https://cedars-sinai.org/globalcollaborations)  
 in f @  @Cedars-Sinai International

At Cedars-Sinai,  
care is tailored for you.

# contents



## UNITED STATES HOSPITALS

- 2 NIH launches four major research initiatives targeting childhood cancer, autism and disease modelling
- 5 Cedars-Sinai International: From the UAE to Los Angeles: Double transplant at Cedars-Sinai saves young patient
- 6 Mayo Clinic: How Mayo Clinic's research revolution is saving millions in healthcare costs while transforming patient outcomes
- 8 Baptist Health: Next-generation MRI-guided radiation therapy: Achieving long-term remission in advanced bladder cancer
- 10 Children's Hospital Los Angeles: Shaping the future of complex pediatric care: The Center for Global Health at Children's Hospital Los Angeles
- 12 Texas Children's Hospital: A global destination for specialized care



### Publisher

Michael Hurst  
Michael@MiddleEastHealth.com

### Editor

Callan Emery  
editor@MiddleEastHealth.com

### Editorial Consultants

Dr Gamal Hammad, Dr Peter Moore, Harry Brewer

### Middle East Editorial Office

PO Box 72280, Dubai, UAE  
Telephone: (+9714) 391 4775  
editor@MiddleEastHealth.com

### Marketing Manager

Foehn Sarkar  
Telephone: (+9714) 391 4775 | Fax: (+9714) 391 4888  
marketing@MiddleEastHealth.com

### Subscription & Admin Manager

Savita Kapoor  
Telephone: (+9714) 391 4775 | Fax: (+9714) 391 4888  
Savita@MiddleEastHealth.com

### Advertising Sales

PO Box 72280, Dubai, UAE  
marketing@MiddleEastHealth.com

### Americas, France

Joy Sarkar  
P O Box 72280, Building No.2  
2nd Floor, Dubai Media City  
Dubai, United Arab Emirates  
Tel: +971 4 391 4775 Fax: +971 4 391 4888  
Joy@MiddleEastHealth.com

### Japan

Mr Katsuhiko Ishii  
Ace Media Service Inc  
12-6, 4-chome, Adachi-ku, Tokyo 121-0824, Japan  
Tel: +81-3-5691-3335 | Fax: +81-3-5691-3336  
Email: amskatsu@dream.com

### China

Miss Li Ying  
Medic Time Development Ltd,  
Flat 1907, Tower A, Haisong Building, Tairan 9th Road,  
Futian District, Shenzhen, China 518048  
Tel: +86-755-239 812 21 | Fax: +86-755-239 812 33  
Email: medic8@medicetime.com

### Taiwan

Larry Wang  
Olympia Global Co Ltd  
7F, No.35, Sec 3, Shenyang Rd, Taichung  
Taiwan 40651 | P O Box: 46-283 Taichung Taiwan 40799  
Tel: +886- (4)-22429845 | Fax: +886- (4)-23587689  
Email: media.news@msa.hinet.net

Middle East Health is published by Hurst Advertising FZ LLC,  
Dubai Media City, License Number: 30309  
UAE National Media Council - Approval Number: 2294781.

### Middle East Health online

www.MiddleEastHealth.com



Middle East Health is printed by Masar Printing and Publishing.  
www.masarprint.com



# NIH launches four major research initiatives targeting childhood cancer, autism and disease modelling

The US National Institutes of Health has unveiled four major initiatives that promise to reshape how scientists understand and treat disease. The near-quarter-billion-dollar investment signals an aggressive pivot toward artificial intelligence, human-relevant model systems, and integrated health frameworks – moves that could deliver breakthroughs for patients in the United States and worldwide.

The announcements, rolled out across two intensive weeks in September, share a common ambition: leveraging massive datasets and emerging technologies to crack problems that have stymied researchers for generations. From pediatric malignancies to autism spectrum disorder, NIH is betting that the future of medicine lies in data-driven discovery, reproducible human-based models, and understanding the body as an integrated system rather than isolated parts.

## **Federal Government doubles investment AI-driven pediatric oncology research**

The Department of Health and Human Services revealed on September 30 that funding for the Childhood Cancer Data Initiative will surge from \$50 million to \$100 million annually, following an executive order signed by President Trump. The initiative, originally established in 2019, aims to harness data infrastructure to accelerate development of improved

diagnostics, treatments, and prevention strategies for pediatric malignancies.

The doubling of resources comes as pediatric cancer remains the leading cause of disease-related death for children in the United States, with incidence climbing more than 40% since 1975. Health and Human Services Secretary Robert F. Kennedy, Jr., NIH Director Jay Bhattacharya, and National Cancer Institute Director Anthony Letai gathered at the White House to mark the executive order signing.

We are dedicated to using every innovative method and technology at our disposal in our fight against childhood cancer. By doubling down on this mission with AI, we are ensuring that state-of-the-art science is being leveraged to provide answers about these diseases that would otherwise be out of reach.

– NIH Director Jay Bhattacharya, M.D., Ph.D.

“For too long, families have fought childhood cancer while our systems lagged behind,” said Secretary Kennedy. “President Trump is changing that. We will harness American innovation in artificial intelligence to find cures for pediatric cancer.”

The expanded funding enables federal agencies to deploy AI technologies to extract maximum value from electronic health records and insurance claims data, informing research priorities and clinical trial design. Critically, the initiative maintains parental control over children’s health information while creating data infrastructure for researchers.

“We are dedicated to using every innovative method and technology at our disposal in our fight against childhood cancer,” said NIH Director Jay Bhattacharya, M.D., Ph.D. “By doubling down on this mission with AI, we are ensuring that state-of-the-art science is being leveraged to provide answers about these diseases that would otherwise be out of reach.”

For newly appointed NCI Director Anthony Letai, M.D., Ph.D., who assumed his position on September 29, the announcement provided an auspicious beginning to his tenure. “I cannot think of a better way to begin my tenure at NCI than to redouble our efforts to support our youngest patients and their families facing rare leukemias and other cancers. We will not stop until childhood cancer is a thing of the past.”

### **Standardized organoid facility transforms translational research infrastructure**

On September 25, NIH announced the establishment of the Standardized Organoid Modeling Center, the nation’s first

dedicated facility for developing reproducible, patient-centered organoid methodologies. With \$87 million in contracts for the initial three-year phase, the center will be housed at the Frederick National Laboratory for Cancer Research, Frederick, Maryland.

Organoids – miniaturized, three-dimensional tissue constructs that recapitulate organ structure and function – offer compelling alternatives to animal models in biomedical research. However, most organoid protocols currently emerge from academic laboratories through iterative experimentation, creating substantial reproducibility challenges that impede scientific progress. The new center addresses these limitations through systematic application of artificial intelligence, robotics, and diverse human cell sources.

“This groundbreaking initiative will transform how we conduct biomedical research through innovative approaches to advancing human-based technologies,” said NIH Director Dr. Jay Bhattacharya. “By creating standardized, reproducible, and accessible organoid models, we will accelerate drug discovery and translational science, offering more precise tools for disease modeling, public health protection, and reducing reliance on animal models.”

The center will initially prioritize organoid models of hepatic, pulmonary, cardiac, and intestinal tissues, with planned expansion to additional organ systems and disease-specific models. Significantly, the center will provide open access to protocols, datasets, and physical organoid samples, fostering global collaboration.

“The NIH SOM Center is truly a first of its kind,” said Nicole Kleinstreuer, Ph.D., Acting NIH Deputy Director for Program

Coordination, Planning, and Strategic Initiatives. “It will serve as a national resource to scientists at NIH and investigators from around the country and the world, offering a unique combination of AI and machine learning to develop world-class organoid protocols, advanced robotics for large-scale production, and open-access repositories for physical samples and digital resources.”

### **Autism data science initiative mobilizes exposomics approach**

On September 22, NIH launched the Autism Data Science Initiative, a research program harnessing large-scale data resources to investigate contributors to autism spectrum disorder etiology and rising prevalence. More than \$50 million in awards support 13 projects integrating genomic, epigenomic, metabolomic, proteomic, clinical, behavioral and autism services data.

The initiative responds to dramatic increases in autism prevalence in the United States, rising from fewer than 1 in 2,000 children in the 1970s to approximately 1 in 31 today, according to Centers for Disease Control and Prevention data.

“Our Autism Data Science Initiative will unite powerful datasets in ways never before possible,” said NIH Director Jay Bhattacharya, M.D., Ph.D. “By bringing together genetics, biology, and environmental exposures, we are opening the door to breakthroughs that will deepen our understanding of autism and improve lives.”

A defining feature of the initiative is deployment of exposomics – comprehensive investigation of environmental, medical, and lifestyle factors integrated with genetic and biological data. Projects

will examine diverse influences, including environmental contaminants such as pesticides and air pollutants, maternal nutrition and diet, perinatal complications, psychosocial stress, and immune responses during pregnancy and early development.

Independent replication and validation centers will test models across diverse populations, ensuring transparency, reproducibility, and real-world utility of findings. Each research team will partner with the autism community to shape research directions and ensure perspectives of autistic individuals, caregivers, and service providers inform the initiative.

Awardee institutions and project descriptions are available at <https://reporter.nih.gov>.

### Whole-person health framework integrates physiological systems

On September 17, NIH announced a five-year research initiative to create an integrated knowledge network of healthy physiological function. The program represents a methodological departure from traditional biomedical research, which predominantly organizes around specific organ systems and disease states.

“Biomedical research is largely organized around the study of specific organs and diseases. In contrast, we do much less research on health itself, which is an integrated process involving the whole person,” said Helene M. Langevin, M.D., director of NIH’s National Center for Complementary and Integrative Health, which leads the NIH-wide program.

Whole-person health encompasses comprehensive assessment of multiple physiological systems and their interactions, rather than isolated organ function. For example, multicomponent lifestyle interventions incorporating dietary modification, physical activity and stress management may concurrently improve cardiovascular parameters such as blood pressure, metabolic function including glucose metabolism, and musculoskeletal capacity.

The initiative builds upon the NIH Human Reference Atlas and Human BioMolecular Atlas Program to connect anatomical complexity and functional relationships across organ systems into unified mapping frameworks. Future program stages will link standard clinical measure-

ments to major physiological functions and ultimately construct an interactive model of whole-person health.

Program details are available at: <https://reporter.nih.gov/search/NHCW3mdunUCF3ULUAvilYQ/project-details/11224772#description>

### Convergent strategy: data science meets human-relevant model systems

These four initiatives, while distinct in specific aims, reflect coherent strategic vision at NIH. The agency is deploying massive datasets, artificial intelligence, and sophisticated human-based model systems to yield breakthroughs that have remained elusive through conventional research approaches.

The childhood cancer initiative exemplifies mobilization of existing data infrastructure – electronic health records, insurance claims, genomic databases – through AI to identify intervention opportunities. The organoid center addresses longstanding limitations in translational research: reproducibility deficits and species differences that have hindered translation from animal models to human therapies. The autism data science effort acknowledges that complex disorders require integration of multiple data modalities to disentangle genetic, environmental, and developmental contributors. The whole-person health project recognizes that human physiology functions as an integrated network.

For patients, these investments promise substantial impacts. The childhood cancer initiative could accelerate identification of targeted therapies for rare pediatric malignancies. The organoid center could enable personalized medicine approaches, with patient-derived organoids testing drug responses before treatment decisions. The autism initiative could clarify which environmental and lifestyle factors represent modifiable risks, enabling prevention strategies.

For the global research community, NIH’s commitment to open access and international collaboration amplifies potential impact. The organoid center’s open-access repositories enable worldwide researcher access to standardized protocols and physical samples. The autism data science initiative’s emphasis on replication

across diverse populations ensures findings generalize beyond narrow demographic groups.

### Implementation challenges and global implications

While ambitions are substantial, so too are challenges. Integrating disparate datasets requires technical infrastructure and careful attention to data quality, standardization, and potential biases. AI and machine learning approaches require rigorous validation to ensure reproducibility and generalizability. Organoid technologies remain in development.

Success depends on sustained funding, effective inter-institutional collaboration, and continued research workforce investment. New expertise at the intersection of biological sciences, computational sciences, and engineering will be required. Yet the timing appears propitious. Computational power continues increasing while costs decrease, making sophisticated large dataset analyses increasingly feasible.

For the international research community, these NIH initiatives offer both opportunity and challenge. Global disease burden distribution means insights from these initiatives could have worldwide impact. International collaboration will be essential to realize full investment potential.

These announcements mark a significant moment in American biomedical research. With investments approaching a quarter-billion dollars, the agency is making a substantial commitment to data-driven, technology-enabled, human-centered research approaches. Over coming years, initiative success will be measured by tangible patient benefits. For families facing childhood cancer, success means more children surviving and thriving. For the autism community, success means understanding rising prevalence and supporting autistic individuals across the lifespan.

For patients and families in the United States and globally, these NIH initiatives offer renewed hope that medicine’s future will be built on more solid scientific foundations – foundations reflecting human biological complexity, modern technology power, and the urgency of unmet medical needs. MEH

# From the UAE to Los Angeles: Double transplant at Cedars-Sinai saves young patient



Suhail Alblooshi

At 30 years old, Suhail Alblooshi was facing end-stage heart failure. His lungs were filled with fluid, and emergency hospital visits had become routine. When local medical centers in Dubai could not provide a solution, the UAE's Department of Health initiated contact with Cedars-Sinai International, setting in motion a medical journey that would span continents.

"Our life was in the car. We were always going back and forth to the hospital... It was the only way to get him to sleep," said Fatima Hussain, Suhail's mother, describing the months before his departure to Los Angeles.

## Cross-border care coordination

Suhail, accompanied by his mother and cousin, traveled from Dubai to Cedars-Sinai in September 2022. The Cedars-Sinai International Patient Services team managed all logistics, from travel arrangements to translation services.

"We do everything we can to make sure our international patients feel supported and comfortable throughout their care journey," said Wafik Gobrial, manager of Patient Services at Cedars-Sinai.

The medical center serves over 2,000 international patients from more than 100 countries annually, managing complex cases requiring extended care periods away from patients' home countries.

## Critical deterioration

Within weeks of arrival, Suhail's condition worsened dramatically. He experienced cardiac arrest twice and was placed on extracorporeal membrane oxygenation (ECMO) to maintain cardiovascular and pulmonary function. Concurrent kidney failure necessitated dialysis support. Unable to speak or move independently, Suhail

remained in intensive care while his family confronted the possibility of loss.

"More than once, we thought we were going to lose him," said Dr. Farzin Samadi, primary care physician at Cedars-Sinai.

## High-risk dual organ transplant

In February 2023, Suhail was added to the transplant list for both cardiac and renal replacement. A compatible donor match was identified within days. The organs were transported via helicopter through inclement weather, and Suhail was immediately transferred to the operating theater.

The surgical team conducted an eight-hour procedure, performing sequential heart and kidney transplantation. The technical complexity was heightened by the patient's prolonged ECMO support, which had depleted clotting factors and elevated hemorrhage risk.

"Any open-chest procedure carries risks. In Suhail's case, it was even more dangerous. But we never gave up," said Dr. Andriana Nikolova, cardiologist at Cedars-Sinai.

The post-operative period required careful immunosuppression management to prevent organ rejection while monitoring for infectious complications.

## Return to normal life

By December 2023, Suhail returned to Dubai with ambulatory assistance, demonstrating progressive strength recovery and improved functional capacity.

"When I came home, it felt like I was seeing it all for the first time. Like I was in a new life... and a new world," Suhail said.

## A remarkable transplant record

In 2024, the Cedars-Sinai Comprehensive Transplant Center and the Smidt Heart Institute achieved a landmark milestone,

completing 682 solid-organ transplants – the highest number performed in a single year at the institution. Patient survival outcomes continued to meet or exceed US national benchmarks, underscoring the program's clinical excellence.


"Behind every transplant is a patient who desperately waited for a chance at life," said Dr. Irene Kim, Director of the Cedars-Sinai Comprehensive Transplant Center. "It is the remarkable generosity of organ donors and their families, that allowed our transplant teams to give 682 patients the chance to have longer and healthier lives."

Cedars-Sinai remains among the top 10 transplant centers in the United States by volume, as recognized by the Organ Procurement and Transplantation Network.

Over the past decade, Cedars-Sinai's transplant program has grown by 84%, driven by advances in organ preservation, an expanded ability to treat complex cases, and innovations such as machine-perfusion technology – allowing successful transplantation of organs once considered unsuitable.

Founded in 1902, Cedars-Sinai is a leading non-profit academic healthcare organization in Los Angeles. Its International Patient Services team provides global patients with multilingual support, priority access to specialists, and coordination with referring entities.

Cedars-Sinai International earned the Global Healthcare Accreditation (GHA) for Medical Travel Services for the second time, recognizing its commitment to delivering world-class, safe, and culturally attuned care for patients traveling from around the world.

• For more information, visit: [www.cedars-sinai.org/international-patients.html](http://www.cedars-sinai.org/international-patients.html) 



# How Mayo Clinic’s research revolution is saving millions in healthcare costs while transforming patient outcomes

As a Category of One global healthcare provider focused on complex and serious diseases, Mayo Clinic stands alone in our ability to transform the most challenging medical cases into successful outcomes. For healthcare leaders in the Middle East, where rising costs and complex conditions strain both budgets and resources, we offer something unprecedented: proven research that dramatically reduces diagnostic errors while cutting costs.

## The hidden crisis costing billions

Healthcare systems worldwide share a devastating secret: diagnostic errors drain billions from insurance providers while causing immeasurable patient suffering. Misdiagnosis leads to wrong treatments, unnecessary procedures, extended hospital stays, and cascading complications that multiply costs exponentially. For complex and serious diseases – exactly where the stakes are highest – these errors prove most costly.

At Mayo Clinic, we’ve spent decades researching this challenge. What we’ve discovered is transforming healthcare economics globally.

## Three breakthroughs that change everything

**1. The 88% discovery: Getting diagnosis right**  
Our groundbreaking research revealed that

88% of patients seeking second opinions at Mayo Clinic receive new or refined diagnoses that fundamentally change their treatment plans. This isn’t a minor adjustment – it’s a complete transformation of the patient’s medical journey.

“When dealing with complex diseases, a correct diagnosis from the start eliminates months of ineffective treatments, prevents unnecessary surgeries, and stops the domino effect of complications that can cost insurers millions per patient,” explains Dr Eric Moore, Medical Director at Mayo Clinic International.


Consider the implications: nearly 9 out of 10 complex cases are being treated incorrectly elsewhere. Each misdiagnosis triggers a chain reaction of wrong medications, failed treatments, and deteriorating conditions requiring

increasingly expensive interventions. Our integrated, multidisciplinary approach breaks this cycle, saving both lives and resources.

## 2. Seeing the invisible: AI that detects cancer 475 days early

We’ve developed revolutionary artificial intelligence that identifies pancreatic cancer on routine CT scans 475 days before traditional diagnosis – with 92% accuracy. This transforms one of medicine’s deadliest diseases into a potentially curable condition.

The financial impact is staggering. Early-stage pancreatic cancer treatment costs approximately \$50,000-\$100,000. Late-stage treatment, involving chemotherapy, radiation, and extended ICU stays, exceeds \$500,000 per patient. By shifting diagnosis



earlier by over a year, we're not just saving lives – we're reducing treatment costs by up to 80%.

"This technology represents the future of medicine – catching disease before symptoms appear, when treatment is simpler, more effective, and far less expensive," says Dr Eric Moore, Medical Director at Mayo Clinic International.

### 3. Proven at scale: Transforming value-based care globally

Theory becomes reality through our proven value-based care models. In one documented case study, we achieved a 97.81% quality score while generating \$32.3 million in cost savings for a major government health insurance program in a single year. This isn't a projection or estimate – it's verified, audited proof that superior care costs less, a model that health systems worldwide can replicate.

We achieved this through value-based care that rewards outcomes, not procedures. By eliminating redundant tests, preventing readmissions, and getting treatment right the first time, we've created a model that insurance providers globally are seeking: better results at lower costs. These principles apply equally whether serving government insurance programs, private insurers, or national health systems.

"We've proven that when you focus on doing the right thing for patients – accurate diagnosis, early intervention, coordinated care – costs naturally decrease while outcomes improve," explains Biju Samkutty, Chief Operating Officer of Mayo Clinic International, on Mayo Clinic's value-based care.

### Beyond individual breakthroughs: Our integrated approach

These three examples represent just the beginning. Across our organization, we're revolutionizing how healthcare is delivered, measured, and paid for. Our approach integrates multiple innovations,

not individual breakthroughs, to solve complex challenges.

We've developed precision medicine protocols that match patients with the exact medications their genetics indicate will work, eliminating expensive trial-and-error prescribing. Our remote monitoring programs keep patients healthy at home, preventing the readmissions that cost insurers billions annually. Our telemedicine platforms deliver Mayo Clinic expertise globally, maintaining diagnostic accuracy while eliminating travel and infrastructure costs.

Every innovation follows the same principle: complex problems require sophisticated solutions, but those solutions should ultimately simplify care and reduce costs. We're not adding layers of complexity – we're using advanced science to make healthcare more straightforward, more effective, and more affordable.

### The global impact

Healthcare organizations worldwide are already experiencing this transformation. Through Mayo Clinic Global Consulting and our international services, we're exporting these proven methodologies to healthcare systems across continents. We help clients implement diagnostic excellence programs, deploy AI tools, establish precision medicine initiatives, and create value-based payment models that align incentives with outcomes.

For Middle Eastern healthcare systems,

where the burden of complex diseases like diabetes, cardiovascular disease, and cancer continues to grow, our research offers a pathway to sustainable, high-quality care. We understand the unique challenges you face – rapidly growing populations, increasing chronic disease prevalence, and the need to provide world-class care while managing costs.

Our research proves that these challenges have solutions. By working with Mayo Clinic, you gain access not just to our technologies and protocols, but to our decades of experience transforming the impossible into the routine.

### We're here to help

The choice facing healthcare leaders today is clear: continue struggling with rising costs and diagnostic errors, or embrace proven innovations that deliver better outcomes at lower costs. Every day you wait leads to more misdiagnoses, more unnecessary treatments, and millions in preventable expenses.

We're here to help you transform your healthcare system. Our team of experts is ready to discuss how Mayo Clinic's research-proven innovations can address your specific challenges. Whether you're an insurance provider seeking to reduce claims, a healthcare system aiming to improve diagnostic accuracy, or a government authority planning for sustainable healthcare, we have solutions tailored to your needs. MEH

The evidence is clear. The methodologies are proven. The only question is: when will you begin your transformation?


Take the first step today:

Email: [INTERNATIONALCOLLABORATE@mayo.edu](mailto:INTERNATIONALCOLLABORATE@mayo.edu)

Call Mayo Clinic International: +1 507-422-5292

Join the growing number of global healthcare leaders who've discovered that with Mayo Clinic by your side, exceptional patient care and financial sustainability aren't competing goals – they're complementary achievements. Contact us now to learn how our research can transform your healthcare challenges into success stories.

# Next-generation MRI-guided radiation therapy: Achieving long-term remission in advanced bladder cancer



Dr. Michael Chuong, Radiation Oncologist, Baptist Health Miami Cancer Institute

When traditional cancer treatments reach their limits, innovation becomes hope. At Baptist Health Miami Cancer Institute, that innovation is transforming patient outcomes through next-generation MRI-guided radiation therapy — a groundbreaking approach that is redefining what’s possible for patients with advanced or metastatic disease.

This advanced technology, available exclusively at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida, combines the precision of magnetic resonance imaging (MRI) with real-time adaptive radiation therapy. The result: treatment so precise that it targets tumors with unprecedented accuracy while sparing surrounding healthy tissue — especially in anatomically complex regions like the abdomen or pelvis.

## A new era in radiation oncology

Radiation therapy has long been a cornerstone of cancer treatment, but traditional systems often rely on static imaging that cannot account for the subtle movements of internal organs. The MRIdian Linac system, however, enables continuous, real-time visualization of the tumor during treatment. Physicians can adapt each session to changes in the patient’s anatomy, ensuring optimal dose

delivery even as tumors shrink or shift.

“This technology allows us to individualize every treatment,” explains Radiation Oncologist Dr. Michael Chuong, one of the pioneers of MRI-guided radiation therapy at Baptist Health Miami Cancer Institute. “We can escalate radiation doses to tumor tissue with extreme precision, even in areas surrounded by vital organs. That’s a major step forward in achieving long-term control — or in some cases, remission.”

## A story of remarkable recovery

One of the most compelling examples of this innovation involves a patient with metastatic bladder cancer who had exhausted all other treatment options, including chemotherapy and immunotherapy. The team at Baptist Health Miami Cancer Institute delivered a series of precisely targeted MRI-guided radiation sessions to three tumor sites — the adrenal gland, abdominal wall, and lymph nodes.

Within months, all tumors regressed completely. More than five years later, the patient remains in long-term remission, with no need for additional systemic therapy and a return to a full quality of life.

“This case demonstrates the power of image-guided, adaptive therapy,” says Dr. Chuong. “It’s not just about prolonging life; it’s about giving patients meaningful years with their loved ones.”

## Transforming the future of cancer care


The success of MRI-guided therapy extends beyond a single patient story. The technology has shown promise in multiple tumor types, including pancreatic, liver, prostate, and lung cancers. Early results from clinical trials, such as the SMART ONE phase 2 study, indicate that single-session, high-dose MRI-guided radiation may be both safe and effective, potentially reducing the number of visits while improving tumor control.



This paradigm shift is gaining global attention — particularly among leading institutions across the Middle East seeking advanced, minimally invasive solutions for complex cancers. With its state-of-the-art platforms and multidisciplinary expertise, Baptist Health Miami Cancer Institute serves as a regional reference center for training, protocol development, and collaborative research.

“Our goal is to share knowledge and technology that elevate outcomes everywhere,” adds Dr. Chuong. “Through partnerships with leading hospitals across the world, we’re working together to expand access to precision oncology.”

As cancer care continues to evolve, Baptist Health Miami Cancer Institute remains committed to leading through innovation, compassion, and collaboration — redefining what’s possible for patients everywhere.

- For more information or to schedule an appointment, call +1 786-596-2373, email [International@BaptistHealth.net](mailto:International@BaptistHealth.net), or visit: [BaptistHealth.net/international](http://BaptistHealth.net/international). 



# Baptist Health

## International



# Welcome to **Award-Winning** Cancer Care.

Baptist Health Cancer Care is once again recognized by U.S. News & World Report as one of the top cancer care programs in the nation. This year, Baptist Health Miami Cancer Institute earned High Performing ratings in complex cancer care, colon cancer surgery, prostate cancer surgery, lung cancer surgery, and in treating patients with leukemia, lymphoma, and myeloma. The Eugene M. & Christine E. Lynn Cancer Institute also received high performing ratings in colon cancer surgery, gynecological cancer surgery, and in treating patients with leukemia, lymphoma, and myeloma.



Scan to learn more

**Don't delay care.**  
**Better cancer care is here.**

786-596-2373

[International@BaptistHealth.net](mailto:International@BaptistHealth.net)



# Shaping the future of complex pediatric care: The Center for Global Health at Children's Hospital Los Angeles



At Children's Hospital Los Angeles, complex care is our everyday routine.

As a leader in pediatric medicine for nearly 125 years and one of the world's premier destinations for leading-edge specialty care and treatment, CHLA is proud to extend its expertise to families and health care partners across the Middle East and beyond through the Center for Global Health.

Each year, thousands of families from around the world turn to CHLA for hope and healing. From rare cancers and congenital heart defects to advanced gene therapies and neurosurgical interventions, CHLA's multidisciplinary teams deliver world-class care for the most challenging pediatric conditions.

Our internationally renowned centers of expertise offer treatments in:

- Pediatric oncology, including CAR T-cell therapy and bone marrow transplantation
- Neurology and epilepsy surgery
- Orthopedic and spinal deformities
- Congenital heart disease and cardiac surgery
- Cell and gene therapy for rare genetic disorders

## A trailblazer in complex pediatric care

CHLA is consistently ranked one of the top five pediatric centers globally and has been distinguished among the top 10 pediatric hospitals in the United States for 17 years in a row by U.S. *News & World Report*.

Additionally, six individual subspecialties earned top 10 recognition, including orthopedics, cancer, gastroenterology and GI surgery, urology, diabetes and endocrinology, and neurology and neurosurgery.

These specialized programs unite world-renowned clinical leaders dedicated to advancing pediatric care through groundbreaking research, next-generation technologies, and innovative treatments. Our Center for Global Health serves as the gateway for international patients, offering



seamless access to CHLA's most advanced services and specialists.

## Comprehensive support for international families

Navigating complex medical care in a foreign country can be overwhelming. That's why CHLA's Center for Global Health offers a full suite of concierge services for international families, helping to alleviate stress and streamline processes for both medical and non-medical needs, every step of the way.

When patients arrive at CHLA, they receive a personalized treatment plan developed by a multidisciplinary team of experts, ensuring the highest standard of care tailored to their unique needs.

CHLA's concierge team ensures families feel supported and empowered, from coordinating appointments and managing travel logistics to providing language interpretation and cultural guidance. Families also receive psychosocial support, financial counseling, and educational resources so they can focus on what matters most: their child's health and recovery.

## Guiding global pediatric care standards

CHLA's impact extends far beyond Los Angeles. Through strategic partnerships,

training programs, and knowledge exchange, we collaborate with health care institutions across the Middle East to elevate standards of pediatric care. Our clinicians provide education and mentorship worldwide, helping to build sustainable health care capacity in local communities.

## Your partner in pediatric excellence

At Children's Hospital Los Angeles, we don't just treat patients – we transform lives and shape the global future of complex pediatric health care. The Center for Global Health represents the pinnacle of this mission, combining compassion, expertise, and innovation to improve the health of children worldwide. MEH

### CHILDREN'S HOSPITAL LOS ANGELES CENTER FOR GLOBAL HEALTH

For international patient referrals, contact us at: [internationalpatientreferrals@chla.usc.edu](mailto:internationalpatientreferrals@chla.usc.edu) or +1-323-361-8737.

- For more information on our Center for Global Health, visit us at: [CHLA.org/GlobalHealth](https://CHLA.org/GlobalHealth)

Every specialist, every breakthrough,  
every innovation — All focused on  
your child's extraordinary care.

[CHLA.org/GlobalHealth](https://chla.org/globalhealth)



# Complex care is our everyday routine



Children's Hospital  
LOS ANGELES. 

# Texas Children's Hospital:

## A global destination for specialized care

Texas Children's Hospital stands as a leading global destination for specialty and subspecialty care for children and women, serving patients from more than 70 countries. The 2025-26 edition of U.S. News & World Report's Best Children's Hospitals ranked Texas Children's among the best in the nation, with all 10 departments ranked in the top 10 and over half in the top 5.

The hospital's International and Destination Medicine Program is the central pillar for its global patients. This team of experts is dedicated exclusively to meeting the needs of international patients and their families, working with them before, during, and after their visit to Houston. The program's goal is to provide professional and personalized care to all patients and their families.



### The International & Destination Medicine Program: Your partner in care

The program provides comprehensive support for international patients and their families, serving as a single point of contact throughout the care journey. Key services include:

- Serving as the primary liaison for families, referring physicians, and international payors.
- Coordinating all aspects of care before, during, and after the Houston visit.
- Ensuring language and distance are not barriers to world-class treatment.
- Providing personalized support tailored to each family's unique needs.
- Managing logistics and care coordination for a seamless experience.

This commitment to excellence is demonstrated across a wide range of top-ranked pediatric services. The Heart Center has been ranked #1 in the nation for pediatric cardiology and heart surgery for nine years in a row. The Cancer and Hematology Center is one of the largest pediatric cancer and blood disorder programs in the U.S., known for pioneering clinical trials. This

year, for the first time ever, our Neurology and Neurosurgery department ranked #1 in the nation providing comprehensive care from the common to some of the rarest, most complex conditions in the world. The Department of Surgery is home to the largest comprehensive team of surgeons in the country, completing 43,700 operating room cases annually.


For women's services, the hospital offers comprehensive care. The Pavilion for Women is a dedicated facility focusing on high-risk births and a full continuum of obstetrics and gynecology care. The Fetal Center is one of only a few worldwide to offer a full spectrum of fetal diagnostic and intervention therapies. Additionally, the Family Fertility Center provides advanced fertility treatments.

Beyond direct patient care, Texas Children's Hospital, in partnership with Baylor College of Medicine, provides leadership in international education and fosters an educational environment that embraces multi-cultural perspectives. The hospital offers support, resources, and educational tools to help international healthcare providers deliver the best



patient care possible.

For physicians and families seeking highly specialized medical care, Texas Children's Hospital provides a proven, ranked, and reliable destination. Its combination of clinical expertise, a dedicated international program, and a commitment to global collaboration makes it a definitive choice for children and women in need of advanced treatment.

- To learn more about the International and Destination Medicine Program, visit: [www.texaschildrens.org/international](http://www.texaschildrens.org/international). 

# #1

# for your #1

Ranked among the best in the nation for 17 years, our commitment is shown through elite, #1-ranked programs in Cardiology, Neurology and Pulmonology. This world-class care is accessible via our International and Destination Medicine Program, providing personalized support every step of the way—the standard we bring to all care, from pioneering research to expanding possibilities.



## Top in the U.S. in every pediatric specialty

- No. 1** Cardiology & Heart Surgery
- No. 1** Neurology & Neurosurgery
- No. 1** Pulmonology & Lung Surgery
- No. 2** Neonatology
- No. 2** Nephrology (Kidney Disorders)
- No. 2** Urology
- No. 5** Diabetes & Endocrinology
- No. 5** Gastroenterology & GI Surgery
- No. 5** Orthopedics
- No. 9** Cancer

Behavioral health earned the highest designation currently available



For more information, visit [texaschildrens.org/best](https://texaschildrens.org/best)  
For international patient referrals,  
email [international@texaschildrens.org](mailto:international@texaschildrens.org)



Texas Children's  
Hospital®

# THERE'S ONLY 1



## Mayo Clinic is the No. 1 hospital in the world.

Newsweek 2025 | Rochester, Minnesota

Mayo Clinic sets the standard as the best hospital in the world. Our world-class experts from every medical specialty work together to give each patient exactly the care they need. Mayo Clinic is the global destination for patients with serious or complex conditions who need certainty, options, and hope.

To learn more about  
requesting an appointment,  
scan the QR code.

